Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 15:39:128.
doi: 10.11604/pamj.2021.39.128.27726. eCollection 2021.

Predictors of mortality and treatment success of multi-drug resistant and Rifampicin resistant tuberculosis in Zimbabwe: a retrospective cohort analysis of patients initiated on treatment during 2010 to 2015

Ronnie Matambo  1 , George Nyandoro  2 , Charles Sandy  3 , Tendai Nkomo  3 , Shungu Mutero-Munyati  1 , Sungano Mharakurwa  4 , Elliot Chikaka  4 , Mkhokheli Ngwenya  5 , Gilchriste Ndongwe  6 , Vongai Mildred Pepukai  1
Affiliations

Predictors of mortality and treatment success of multi-drug resistant and Rifampicin resistant tuberculosis in Zimbabwe: a retrospective cohort analysis of patients initiated on treatment during 2010 to 2015

Ronnie Matambo et al. Pan Afr Med J. .

Abstract

Introduction: Zimbabwe is one of the 30 countries globally with a high burden of multidrug-resistant TB or rifampicin-resistant TB. The World Health Organization recommended that patients diagnosed with multidrug-resistant TB be treated with 20-24 month standardized second-line drugs since 2010. However, factors associated with mortality and treatment success have not been systematically evaluated in Zimbabwe. The Objective of the study was to assess factors associated with Mortality and treatment success among multidrug-resistant-TB patients registered and treated under the National Tuberculosis programme in Zimbabwe.

Methods: the study was conducted using secondary data routinely collected from the National tuberculosis (TB) programme. Categorical variables were summarised using frequencies and a generalized linear model with a log-link function and a Poisson distribution was used to assess factors associated with mortality and treatment success. The level of significance was set at P-Value < 0.05.

Results: patient antiretroviral therapy (ART) status was a significant associated factor of treatment success or failure (RRR = 3.92, p < 0.001). Patients who were not on ART had a high risk of death by 3.92 times compared to patients who were on ART. In the age groups 45 - 54 years (relative risk ratios (RRR) = 1.41, p = 0.048), the risk of death was increased by 1.41 times compared to other age groups. Patients aged 55 years and above (RRR = 1.55, p = 0.017), had a risk of dying increased by 1.55 times compared to other age groups. Diagnosis time duration of 8 - 30 days (RRR = 0.62, p = 0.022) was found to be protective, a shorter diagnosis time duration between 8 to 30 days reduced the risk of TB deaths by 0.62 times compared to longer periods. Missed TB doses of > 10% (RRR = 2.03, p < 0.001) increased the risk of MDR/RR-TB deaths by 2.03 times compared to missing TB doses of ≤ 10%.

Conclusion: not being on ART when HIV positive was a major significant predictor of mortality. Improving ART uptake among those ART-naïve and strategies aimed at improving treatment adherence are important in improving treatment success rates.

Keywords: ART monitoring; Predictors; TB/HIV co-infections; mortality; rifampicin-resistant tuberculosis; treatment success.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
cumulative survival of MDR/RR-TB patients over time in days
Figure 2
Figure 2
Kaplan-Meier survival estimates among patients registered and commenced on MDR/RR-TB treatment in Zimbabwe stratified by HIV and ART status
See this image and copyright information in PMC

References

    1. World Health Organisation . Geneva: WHO; 2014. Global Tuberculosis Report-2014.
    1. World Health Organisation . Geneva: WHO; 2013. Global Tuberculosis Report - 2013 (WHO/HTM/TB/201311)
    1. World Health Organization (WHO) Geneva: WHO; 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on the surveillance and response.
    1. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One. 2009 Sep 25;4(9):e7186. - PMC - PubMed
    1. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007 Aug 15;196(Suppl 1):S86–107. - PubMed

MeSH terms